APOA1 and type 2 diabetes mellitus: Using a multiple reaction monitoring (MRM) MS approach to detect specific apoA-I tryptic peptides, we have recently analyzed the apoA-I M148 oxidation in a small cohort of T2D patients and healthy controls; the T2D patients were further subgrouped depending on whether they had prior CVD events or not.